Saturday 17 October 2026
Export OLMA’s income statement to Excel — free account
Olema Pharmaceuticals, Inc.
OLMA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 19.6%, free cash flow fell 54.3% and total debt was flat, each against the same quarter a year earlier.
6.58
0.29
−4.22%
Follow OLMA
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 35.73 | 8.25 | 2.00 | 2.45 | 5.56 | 2.86 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 60.27 | 54.88 | 9.68 | 17.79 | 16.78 | 36.26 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 22 | 37 | 74 | 86 | 74 | 96 | 131 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | (2) | (4) | (22) | (71) | (105) | (97) | (129) | (162) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | (2) | (4) | (22) | (71) | (105) | (97) | (129) | (162) | |||||
| Depreciation | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | (0.87) | (1.66) | (3.42) | (1.80) | (2.62) | (2.14) | (2.20) | (1.87) | |||||
| Cash flow | — | — | (0.86) | (1.19) | (2.83) | (1.28) | (2.05) | (1.85) | (1.78) | (1.69) | |||||
| Capex | — | — | 0.00 | 0.00 | (0.01) | (0.04) | (0.01) | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | (0.86) | (1.19) | (2.84) | (1.32) | (2.06) | (1.85) | (1.78) | (1.69) | |||||
| Book value | — | — | 1.22 | (0.48) | 48.16 | 7.20 | 4.94 | 5.61 | 6.96 | 5.50 | |||||
| Shares, m | — | — | 3 | 3 | 7 | 40 | 40 | 45 | 59 | 87 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (2) | (3) | (20) | (51) | (82) | (84) | (104) | (147) | ||||
| Capex | — | — | — | — | 0 | (2) | 0 | 0 | 0 | — | |||||
| Free cash flow | — | — | (2) | (3) | (20) | (52) | (82) | (84) | (105) | (147) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 3 | (1) | 338 | 282 | 192 | 245 | 397 | 464 | ||||
| Total debt | — | — | — | — | — | 2 | 2 | — | — | 3 | |||||
| Net debt | — | — | (3) | 0 | (339) | (285) | (203) | (262) | (434) | (502) | |||||
| Shareholders’ equity | — | — | 3 | (1) | 338 | 285 | 198 | 254 | 409 | 479 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (134.33) | (253.66) | (13.99) | (22.26) | (40.97) | (39.24) | (35.57) | (33.00) | ||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | 26.04 | 51.16 | (14.65) | (22.83) | (43.47) | (42.82) | (39.07) | (36.61) | |||||
Negative figures in brackets.
Charts ten years each
Olema Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| WVE WAVE Life Sciences Ltd. | $628.6M | — (loss-making) | — (loss-making) | −73.88% (below 0%: shrinking) | n/m | −17.59% (below 0%: shrinking) | 100.00% | (3,248.33%) | Compare |
| CLYM Climb Bio, Inc. | $626.6M | — (loss-making) | — | — | n/m | +3.73% (above 0%: growing) | — | 0.00% | Compare |
| NVCT Nuvectis Pharma, Inc. | $618.0M | — (loss-making) | — | — | n/m | −34.57% (below 0%: shrinking) | — | 0.00% | Compare |
| SLDB Solid Biosciences Inc. | $615.5M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −39.56% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ZVRA Zevra Therapeutics, Inc. | $609.9M | 10.5× | 10.5× | +53.25% (above 0%: growing) | −88.71% (below 0%: shrinking) | +670.87% (above 0%: growing) | 96.16% | 42.30% | Compare |
| PHAT Phathom Pharmaceuticals, Inc. | $606.8M | — (loss-making) | — (loss-making) | +88.02% (above 0%: growing) | n/m | +96.86% (above 0%: growing) | 79.68% | (5.34%) | Compare |
| OLMA Olema Pharmaceuticals, Inc. | $601.1M | — (loss-making) | — | — | n/m | −54.33% (below 0%: shrinking) | 0.00% | 0.00% | |
| CRMD CorMedix Inc | $581.5M | 3.0× | 16.5× | +156.52% (above 0%: growing) | +13.79% (above 0%: growing) | +185.90% (above 0%: growing) | 75.66% | 42.10% | Compare |
| SLN Silence Therapeutics PLC Sponsored ADR | $581.1M | — (loss-making) | — (loss-making) | +197.18% (above 0%: growing) | n/m | +106.95% (above 0%: growing) | 97.39% | 0.00% | Compare |
| Median of peers | $612.7M | — | — | +70.64% | — | +50.30% | 87.92% | 0.00% |
Olema Pharmaceuticals, Inc. (OLMA) key facts
- Olema Pharmaceuticals, Inc. (OLMA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, OLMA traded at $6.58, a market capitalization of $601.1 million.
- Return on equity was −36.6% and debt-to-equity 0.01.